Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674440 · ClinicalTrials.gov registry record · Phase 2
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
A Phase 2 study of Congenital Hyperinsulinism and Hyperinsulinism, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT00674440 is a Phase 2 study of Congenital Hyperinsulinism and Hyperinsulinism that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 106 participants, above the 63-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (68% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00674440, a Phase 2 study of Congenital Hyperinsulinism and Hyperinsulinism, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.
Conditions Studied
Interventions
- DRUG F-DOPA
- RADIATION PET scan
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674440
The ClinicalTrials.gov registry entry for NCT00674440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (68% higher). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Congenital Hyperinsulinism appearing as the primary indexed condition, and to 2 interventions - of which F-DOPA is the first listed.
NCT00674440 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00674440 about?
NCT00674440 is a clinical study titled "Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism". Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured ...
What is the current status of trial NCT00674440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2004-12. Estimated completion is 2009-01.
What conditions does trial NCT00674440 study?
This clinical trial studies the following conditions: Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI.
What interventions are being tested in trial NCT00674440?
The interventions under investigation include: F-DOPA (DRUG), PET scan (RADIATION).
Who is sponsoring clinical trial NCT00674440?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674440 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Hyperinsulinism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
RECRUITING · Phase 2
-
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
RECRUITING · Phase 2
-
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
COMPLETED · Phase 2
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
RZ358 Treatment for Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.